ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 32

High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis

Hon Yan Ng1, Stefan Slomp2, Tracy Wilson-Gerwing3, Joan Dietz4, Abid Lodhi5, Tanya Holt6 and Alan Rosenberg3, 1Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Pediatrics, Emergency Medicine, University of Alberta, Edmonton, AB, Canada, 3Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5Regina Qu'appelle Health Region, Regina, SK, Canada, 6University of Saskatchewan, Sasktoon, SK, Canada

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Biomarkers, inflammation and juvenile idiopathic arthritis (JIA), Kawasaki disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, May 20, 2017

Title: Genetics and Pathogenesis Poster Breakout II

Session Type: Abstract Submissions

Session Time: 5:15PM-5:45PM

Background/Purpose: High Mobility Group Box 1 Protein (HMGB1) is a nuclear protein that stabilizes DNA and modulates gene expression.  In sepsis and in certain other systemic inflammatory conditions HMGB1 is released extracellularly to mediate an array of cell signaling pathways that promote downstream release of pro-inflammatory cytokines.  Elevated blood levels of HMGB1 are found in association with sepsis and a variety of conditions characterized by systemic inflammation. The purpose of this study was to determine if HMGB1 levels could serve as a discriminating biomarker in early Kawasaki Disease (KD) compared to new onset systemic juvenile idiopathic arthritis (sJIA).

Methods: Children (age ≤ 16 years) with KD and, for comparison, those with sepsis (systemic inflammatory response syndrome or bacteremia) and other non-infectious/non-inflammatory conditions were prospectively enrolled at the time of hospital admission. Prospectively collected data from new onset, treatment naive sJIA participants were derived from the BBOP Study (Biologically-based Outcome Predictors in JIA; www.bbop.ca). Blood was collected in P100 vacutainers (BD) and plasma stored at -800C until assayed. HMGB1 was measured in duplicate (1:100 dilution) by enzyme immunoassay (Biomatrix). Inter-group differences were compared by independent samples t tests and correlations by Pearson correlation coefficients.

Results:   The study population comprised 70 participants (Table).  HMGB1 levels were significantly higher in KD compared to sJIA (t= 4.19; p<.001; CI= 310-892) and to patients with other conditions (t=2.89; p=.009; CI=140-875) but were not different from HMGB1 levels in sepsis (t=.82; p=0.42; CI=-246-582).  Participants with sJIA had significantly lower levels of HMGB1 compared to those with sepsis (t=2.42; p=.019; CI=73-792) and did not differ from those with other conditions.   HMGB1 levels were significantly higher in younger children (r=.26); children 3 years of age or younger had higher HMGB1 levels than those older than age 3 (p=.028; CI=34-600). There was no correlation between HMGB1 levels and c-reactive protein in any of the groups.  No sex differences in HMGB1levels were observed.

Conclusion:  Results of this study show that HMGB1 levels are significantly higher in children with KD than in sJIA and comparable to levels seen in children with sepsis. HMGB1 levels in sJIA are not different than in children with other non-infectious/non-inflammatory conditions. Further prospective studies in larger cohorts are required to determine if HMGB1 could serve as a biomarker to predict disease course and outcomes in KD and as an early biomarker useful for distinguishing KD from sJIA. Results suggest that HMGB1 has a role in mediating KD pathogenesis and that HMGB1, as a pro-inflammatory mediator, might be a potential target for biologically-based therapy in acute KD.  

 


Disclosure: H. Y. Ng, None; S. Slomp, None; T. Wilson-Gerwing, None; J. Dietz, None; A. Lodhi, None; T. Holt, None; A. Rosenberg, None.

To cite this abstract in AMA style:

Ng HY, Slomp S, Wilson-Gerwing T, Dietz J, Lodhi A, Holt T, Rosenberg A. High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/high-mobility-group-box-1-protein-in-children-with-kawasaki-disease-and-systemic-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-mobility-group-box-1-protein-in-children-with-kawasaki-disease-and-systemic-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology